Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction
Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction
Recruiting · NCT04383262 · Registry updated 2026-09-10Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Fosamprenavir for Laryngopharyngeal Upper Airway Tissue Treatment and Enzyme Reduction | Deglutition Disorders, Digestive System Diseases, Laryngopharyngeal Reflux, digestive system disorder, dyskinesia of esophagus, esophageal disorder, gastroesophageal reflux disease, laryngeal disorder, respiratory system disorder | Recruiting | Phase 2 | 2026-09-10 | NCT04383262 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Medical College of Wisconsin | 201 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Froedtert Hospital | Milwaukee | United States | 24 |